New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
- 4 May 2011
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 60 (2) , 279-290
- https://doi.org/10.1016/j.eururo.2011.04.038
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancerCancer, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancerEuropean Journal Of Cancer, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate CancerScience Translational Medicine, 2010
- Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibodyLab on a Chip, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancerCancer, 2008